Myopathies and elevations of CPK are the most common AEs. Ally et al, 2 in a small clinical trial (n ¼ 17), noted that patients experienced a modest improvement in symptoms within 2 weeks of amlodipine treatment. A study is in progress to evaluate levocarnitine in alleviating HPI-associated muscle spasms (NCT01893892). Elevated CPK has been described for both sonidegib and vismodegib, with monitoring for required for sonidegib but not vismodegib. Significantly, CPK levels were not monitored during vismodegib trials. HPI patients at risk for CPK abnormalities or myopathies, such as those concurrently using a statin, may benefit from periodic monitoring.
Alopecia is the second most common AE. Unlike with chemotherapy, alopecia usually involves less than 50% of the scalp. 3 MacDonald et al 3 recommend concealment measures and minoxidil 2-5% continued for 6 months after therapy.
Dysgeusia is the third most common AE. Le Moigne et al 4 demonstrated a benefit of early nutritional screening for those taking vismodegib, with less weight loss in the intervention group that received nutritional counseling. Significantly, a greater than 5% weight loss can occur without dysgeusia, possibly due to diarrhea, nausea, xerostomia, oral thrush, or abdominal pain. 4 Addressing oral hygiene, reflux disease, low-grade oral infection, and postnasal drip are reported to improve taste sensation in non-HPI patients. 3 While patients who undergo HPI therapy are generally older adults, premenopausal women of childbearing age may experience amenorrhea likely due to reversible follicle-stimulating hormone receptor inhibition. 1 It is essential to counsel primary care physicians on both the teratogenicity and sequelae of ovarian failure because nondermatologists are largely unfamiliar with the side effects of HPIs. As use of HPIs for basal cell nevus syndrome expands to a younger population, a larger number of patients may experience amenorrhea.
Recently, new onset squamous cell carcinomas have been reported during HPI therapy. Zhu et al 5 recommend that a new or persistent ulceration, nodule or erythema in the BCC tumor site should be biopsied if present after 3 months of HPI therapy. We recommend that total body skin exams be conducted during therapy and non-BCC lesions comprehensively treated, because we have identified synchronous occult amelanotic melanoma in 3 of 12 patients considered for HPI therapy. 
